Delivering the Promise of Radiotheranostics
De-risked preclinical drug candidates that meet patient need and market demand: one package to target, diagnose, and treat cancer.
We Build
Pre-Clinical
Radiotheranostic
Candidates
Radiotheranostics detect and treat cancers by combining carefully-selected targeting molecules and radioactive isotopes.
Well-chosen targeting molecules drive specificity, efficiency, efficacy, feedback.
The result is less collateral harm of healthy tissue and better patient outcomes.
Our product is qualified, clinic-ready radiotheranostic candidates to diagnose and treat cancer.